All In Biotech

Drug Trial Radar · NCT07602842

A Study of IDP-001 in Advanced or Metastatic Solid Tumors

A Phase 1/2 Open-label Study of IDP-001 in Advanced or Metastatic Squamous Cell Lung Cancer and Other Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

132

Planned (sponsor's estimate)

Start

Jul 8, 2026

Primary completion

Jun 2028

Study completion Dec 2028

Sponsor

Lead sponsor
InduPro, Inc.Industry
Sponsor type
Industry
First posted
May 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell solid tumors (for example, head and neck, esophageal, cervical, cutaneous).

Conditions

  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Head and Neck Squamous Cell Carcinoma
  • Cutaneous Squamous Cell Carcinoma
  • Squamous Cell Carcinoma of the Cervix
  • Non Squamous Non Small Cell Lung Cancer
  • Squamous Cell Carcinoma of the Esophagus
  • Squamous Cell Carcinoma of the Anus
  • Squamous Cell Carcinoma

Interventions

  • IDP-001Drug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 Part 1: Number of Participants with Dose Limiting Toxicities (DLTs) during Cycle 1Time frame: 3 weeks
  2. Phase 1 Part 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Dose Reduction, Dose Interruption, and Dose DiscontinuationTime frame: Approximately 6 months
  3. Phase 1 Part 2: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by InvestigatorTime frame: Approximately 6 months
  4. Phase 1 Part 2: Duration of Response (DOR) per RECIST Version 1.1 as Assessed by InvestigatorTime frame: Approximately 6 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • START Los Angeles

    Los Angeles, California · Recruiting

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • Community Cancer Center North

    Indianapolis, Indiana · Recruiting

  • Roswell Park Cancer Institute

    Buffalo, New York · Recruiting

  • START New York Long Island

    Lake Success, New York · Recruiting

  • START Dallas Forth Worth

    Fort Worth, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.